Patents Assigned to Reata Pharmaceuticals, Inc.
  • Patent number: 10953020
    Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
    Type: Grant
    Filed: November 8, 2017
    Date of Patent: March 23, 2021
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventor: Colin J. Meyer
  • Publication number: 20210040142
    Abstract: Disclosed herein are compounds of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders, including those associated with inflammation and cancer.
    Type: Application
    Filed: July 20, 2020
    Publication date: February 11, 2021
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Xin JIANG, Christopher F. BENDER, Ha DO, Haizhou SUN, Melean VISNICK
  • Patent number: 10898499
    Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Grant
    Filed: July 31, 2019
    Date of Patent: January 26, 2021
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick
  • Publication number: 20200239410
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: February 10, 2020
    Publication date: July 30, 2020
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric ANDERSON, Xin JIANG, Melean VISNICK
  • Patent number: 10717755
    Abstract: Disclosed are co-crystal forms of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3?-fluoro-[1,1?-biphenyl]-2-yl)ethyl)-acetamide and L-proline or D-proline, their pharmaceutical compositions, processes of manufacture, and methods of use for treating neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: July 21, 2020
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Xin Jiang, John Allen Walling, Melanie J. Bevill, Christopher S. Seadeek, Jared P. Smit
  • Publication number: 20200207706
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Application
    Filed: December 3, 2019
    Publication date: July 2, 2020
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric ANDERSON, Gary L. BOLTON, Bradley CAPRATHE, Xin JIANG, Chitase LEE, William H. ROARK, Melean VISNICK
  • Publication number: 20200129530
    Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Application
    Filed: July 31, 2019
    Publication date: April 30, 2020
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Xin JIANG, Christopher F. BENDER, Melean VISNICK
  • Publication number: 20200131148
    Abstract: Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR? and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.
    Type: Application
    Filed: December 16, 2017
    Publication date: April 30, 2020
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Xin JIANG, Christopher F. BENDER, Melean VISNICK, Martha R. HOTEMA, Zachary S. SHELDON, Chitase LEE, Bradley William CAPRATHE, Gary BOLTON, Brian KORNBERG
  • Patent number: 10556858
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: February 11, 2020
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Xin Jiang, Melean Visnick
  • Patent number: 10501489
    Abstract: Disclosed herein are novel C17-alkanediyl and alkenediyl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: December 10, 2019
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Christopher F. Bender, Xin Jiang, Eric Anderson, Melean Visnick
  • Publication number: 20190350941
    Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
    Type: Application
    Filed: November 8, 2017
    Publication date: November 21, 2019
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventor: Colin J. MEYER
  • Patent number: 10398711
    Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: September 3, 2019
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick
  • Patent number: 10105372
    Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.
    Type: Grant
    Filed: April 12, 2011
    Date of Patent: October 23, 2018
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Colin J. Meyer, Warren Huff
  • Patent number: 10093614
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: October 9, 2018
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Xin Jiang, Melean Visnick
  • Publication number: 20180265455
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Application
    Filed: January 4, 2018
    Publication date: September 20, 2018
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric ANDERSON, Gary L. BOLTON, Bradley CAPRATHE, Xin JIANG, Chitase LEE, William H. ROARK, Melean VISNICK
  • Publication number: 20180235981
    Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Application
    Filed: January 3, 2018
    Publication date: August 23, 2018
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Xin JIANG, Christopher F. BENDER, Melean VISNICK
  • Publication number: 20180237383
    Abstract: This invention provides novel compounds comprising the following anti-inflammatory pharmacore: wherein X, R1 and R2 are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: October 24, 2017
    Publication date: August 23, 2018
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric ANDERSON, Gary L. BOLTON, Deborah A. FERGUSON, Xin JIANG, Robert M. KRAL, JR., Patrick M. O'BRIEN, Melean VISNICK
  • Publication number: 20180161311
    Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.
    Type: Application
    Filed: August 14, 2017
    Publication date: June 14, 2018
    Applicants: REATA PHARMACEUTICALS, INC., TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Michael B. SPORN, Karen T. LIBY, Gordon W. GRIBBLE, Tadashi HONDA, Robert M. Kral, Colin J. MEYER
  • Publication number: 20180127380
    Abstract: Disclosed herein are compounds of the formula: (I), wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used as antioxidant inflammation modulators. In some aspects, the present disclosure provides methods wherein the compounds and composition described herein are used for the treatment of diseases and disorders associated with inflammation and cancer.
    Type: Application
    Filed: February 12, 2016
    Publication date: May 10, 2018
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Xin JIANG, Bradley William CAPRATHE, Chitase LEE, Gary BOLTON, Christopher F. BENDER, Melean VISNICK
  • Patent number: 9889143
    Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Grant
    Filed: November 11, 2016
    Date of Patent: February 13, 2018
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick